Reportlinker Adds Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising Agents Emerge for BRCA Positiv

NEW YORK, April 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patients

http://www.reportlinker.com/p0487123/Pipeline-Insight-Cancer-Overview--Breast-and-Gynecological-Cancers---Promising-agents-emerge-for-BRCA-positive-patients.html

Introduction

The three tumor types covered in this report are set to account for just over 585,000 new cancer cases in 2010 with forecasts of over 656,000 new cases in 2019. Collectively the drugs profiled in this report for breast and ovarian cancer are forecast to achieve almost $3.0 billion in sales in the seven major pharmaceutical markets in 2019.

Scope of this research

Examination of the breast and ovarian cancer pipelines with in-depth clinical and commercial profiles of Phase III candidates Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2019 with product-specific assumptions Segmentation and analysis of the current breast and ovarian cancer pipelines by phase of development, drug class and company Insight and analysis of breast, ovarian and cervical cancer markets including commercial opportunity, epidemiology and discussion of unmet needs Research and analysis Highlights

There are currently 94 drugs in clinical development for breast cancer, of which 8 are in late phase development (preregistration, Phase III or pivotal Phase II trial). Collectively, the drugs forecast in this report for breast cancer are forecast to achieve $1.1 billion in sales by 2019.

There are currently 41 drugs in the pipeline for ovarian cancer, of which 10 are in late-phase development. Collectively, the drugs in late-phase development for ovarian cancer profiled in this report are forecast to achieve $1.8bn in sales by 2019.

R&D interest in cervical cancer is limited compared with other cancers and as a result there is a lack of novel drug candidates in late-phase development. Despite poor outcomes and prognoses for late-stage patients, recent focus has been directed towards preventative strategies rather than treatment.

Key

Reasons to Purchase this research

Identify key drugs within the breast and ovarian cancer pipelines based on sales forecasts and Datamonitor drug assessment Characterize unmet needs within breast, ovarian and cervical cancers and assess the potential for pipeline products to fulfill them Assess the shifting breast, ovarian and cervical cancer market dynamics and how future treatment will incorporate pipeline products

TABLE OF CONTENTS

Overview 1

Catalyst 1

Summary 1

About Datamonitor Healthcare 2

About the Oncology pharmaceutical analysis team 2

Executive Summary 3

Strategic scoping and focus 3

Datamonitor insight into the breast, ovarian, and cervical cancer markets 3

Contributing experts 4

Related reports 5

Upcoming reports 5

1. Pipeline Overview and Dynamics 9

Key findings 9

Pipeline summary: breast cancer 10

Pipeline summary: ovarian cancer 13

Pipeline summary: cervical cancer 16

2. R&D Approach 17

Key findings 17

Clinical trial design in cancer 17

3. Epidemiology 21

Introduction 21

Key points 21

Epidemiologic forecasting of breast, ovarian, and cervical cancers 23

Epidemiologic results: breast cancer 27

Epidemiologic results: ovarian cancer 35

Epidemiologic results: cervical cancer 39

Strengths of Datamonitor's epidemiologic projections 44

Conclusions 44

4. Market Overview: Breast Cancer 45

Disease definition 45

Patient segmentation 46

Current treatment options 50

Unmet needs in breast cancer 56

Target product profile versus current level of attainment 59

5. Pipeline Analysis and Forecasts: Breast Cancer 61

Afatinib (BIBW-2992; Boehringer Ingelheim) 67

Afinitor (everolimus; Novartis) 72

Halaven (eribulin mesylate; Eisai) 81

Iniparib (BSI-201; BiPar Sciences/Sanofi-Aventis) 90

Neratinib (HKI-272; Pfizer) 98

Omnitarg (pertuzumab; Genentech/Roche/Chugai) 104

Ramucirumab (IMC-1121B; Eli Lilly) 113

Trastuzumab-DM1 (ImmunoGen/Genentech/Roche/Chugai) 119

Votrient (pazopanib; GlaxoSmithKline) 127

6. Market Overview: Ovarian Cancer 135

Definition 135

Current treatment options 140

Target product profile versus current level of attainment 155

7. Pipeline Analysis and Forecasts: Ovarian Cancer 157

Abagovomab (ACA-125; Menarini/CellControl BioMedical) 162

AMG 386 (Amgen) 168

Avastin (bevacizumab; Genentech/Roche/Chugai) 174

Farletuzumab (MORAb-003; Morphotek/Eisai) 186

Karenitecin (cositecan; BNP-1350; BioNumerik) 193

Tarceva (erlotinib; Genentech/Roche/Chugai/OSI) 199

Vargatef (intedanib/BIBF-1120; Boehringer Ingelheim) 205

Votrient (pazopanib; GlaxoSmithKline) 210

Olaparib (AZD2281; AstraZeneca) 218

8. Market Overview Cervical Cancer 222

Disease definition 222

Patient segmentation 223

Current treatment options 227

Target product profile versus current level of attainment 234

Bibliography 236

Chapter 1: Pipeline Overview and Dynamics 236

Chapter 2: R&D approach 236

Chapter 3: Epidemiology 237

Chapter 4: Market Overview: Breast Cancer 239

Chapter 5: Pipeline Analysis & Forecasts: Breast Cancer 243

Chapter 6: Market Overview: Ovarian Cancer 246

Chapter 7: Pipeline Analysis and Forecasts: Ovarian Cancer 251

Chapter 8: Market Overview: Cervical Cancer 254

Appendix 258

Abbreviations 258

Methodology 258

About Datamonitor 264

Datamonitor consulting 265

Disclaimer 265

To order this report:

: Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patients

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Suggested Articles

Belén Garijo, currently CEO of Merck Healthcare, will succeed Stefan Oschmann as the German company's chief exec when his tenure ends in April 2021.

More than 60 researchers and bioethicists called on Pfizer to take time to collect more COVID-19 vaccine safety data, Bloomberg reports. 

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.